Fibroblast Growth Factor Receptor Stocks List

Recent Signals

Date Stock Signal Type
2021-03-03 BBIO 20 DMA Resistance Bearish
2021-03-03 BBIO MACD Bearish Signal Line Cross Bearish
2021-03-03 BBIO 50 DMA Resistance Bearish
2021-03-03 BPMC 20 DMA Resistance Bearish
2021-03-03 FUSN 20 DMA Resistance Bearish
2021-03-03 FUSN 50 DMA Resistance Bearish
2021-03-03 FUSN Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-03-03 KNTE 20 DMA Resistance Bearish
2021-03-03 NGM MACD Bullish Centerline Cross Bullish
2021-03-03 NGM Crossed Above 50 DMA Bullish
2021-03-03 NGM Crossed Above 20 DMA Bullish

Recent News for Fibroblast Growth Factor Receptor Stocks

Date Stock Title
Mar 3 KNTE Kinnate Biopharma (KNTE) Investor Presentation - Slideshow
Mar 3 BPMC Blueprint says EMA validated Ayvakyt marketing application for systemic mastocytosis
Mar 3 BPMC Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Mar 3 KNTE We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
Mar 2 FUSN Fusion to buy Ipsen's IPN-1087 in pipeline expansion push
Mar 2 NGM NGM Bio starts dosing in early-stage pancreatic cancer study
Mar 2 NGM NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer
Mar 2 FUSN Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Mar 1 BBIO BridgeBio Jumps 6% Pre-Market On FDA Approval For Nulibry
Mar 1 BBIO BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder
Mar 1 BBIO FDA OKs BridgeBio Pharma's Nulibry in severe neurologic damage
Feb 28 BBIO BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
Feb 27 BPMC 15 Fastest Growing Biotech Companies in the US
Feb 27 RLAY Relay Therapeutics: A Long-Term Position In Data-Driven Drug Developer Looks Attractive
Feb 26 BBIO Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?
Feb 25 NGM NGM Bio to Present at the Cowen 41st Annual Health Care Conference
Feb 25 BBIO BridgeBio Pharma EPS misses by $0.16, misses on revenue
Feb 25 BBIO BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
Related Industries: Biotechnology